CytomX Therapeutics to Present at Upcoming September Investor Conferences
05 September 2023 - 10:05PM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of
conditionally activated, localized biologics, today announced that
management will participate in the following investor conferences
in September.
H.C. Wainwright 25th
Annual Global Investment Conference Date: Tuesday,
September 12, 2023 Company Presentation: 11:30 a.m. ET Location:
New York, NY
Cantor Global Healthcare Conference Date:
Tuesday, September 26, 2023 Fireside Chat: 8:10 a.m. ET Location:
New York, NY
Live webcasts of the H.C. Wainwright presentation and Cantor
fireside chat will be available on the Events and Presentations
page of CytomX’s website at www.cytomx.com. In addition, management
will be available for one-on-one meetings with investors who are
registered to attend the conferences.
About CytomX TherapeuticsCytomX’s robust
and differentiated pipeline comprises therapeutic candidates across
multiple treatment modalities including antibody-drug conjugates
(“ADCs”), T-cell engaging bispecific antibodies, and immune
modulators such as cytokines and checkpoint inhibitors. CX-904 is a
conditionally activated T-cell-engaging bispecific antibody
targeting the epidermal growth factor receptor (EGFR) on tumor
cells and the CD3 receptor on T cells, which is partnered with
Amgen. CytomX’s clinical pipeline also includes cancer
immunotherapeutic candidates against validated targets such as the
CTLA-4-targeting Probody therapeutic BMS-986288, partnered
with Bristol Myers Squibb. In addition, CytomX has a
diverse preclinical portfolio of wholly-owned assets including
CX-2051, a conditionally activated ADC directed toward EpCAM, with
potential applicability across multiple EpCAM-expressing epithelial
cancers, and CX-801, an interferon alpha-2b Probody cytokine that
has broad potential applicability in traditionally immuno-oncology
sensitive as well as insensitive (cold) tumors. CytomX has also
established strategic collaborations with multiple leaders in
oncology, including Amgen, Astellas, Bristol Myers
Squibb, Regeneron and Moderna. For more information about
CytomX and how it is working to make conditionally activated
treatments the new standard-of-care in the fight against cancer,
visit www.cytomx.com and follow us on LinkedIn and Twitter.
Probody is a U.S. registered trademark of CytomX Therapeutics,
Inc.
CytomX Contact:Chris OgdenSVP,
Finance and Accounting cogden@cytomx.com (317) 767-4764
Investor and Media
Contact:Stern Investor RelationsStephanie
Ascherstephanie.ascher@sternir.com212-362-1200
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024